Barcelona

• A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects with Metastatic or Unresectable Non-Small Cell Lun … Recruiting
  2023-506539-14-00 3 2025-05-27 Oncology
• Dose Range Finding Study to Access Efficacy and Safety of Tozorakimab in Adults with Uncontrolled Asthma on Medium-to-High Dose Inhaled Cort … Recruiting
  2024-519116-14-00 4 2025-05-27 Asthma
• EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting
  2023-506817-23-01 5 2025-05-23 Metastatic hormone naïve prostate cancer (mHNPC)
• A clinical study of MK-3120 in people with solid tumors (MK-3120-002) Recruiting
  2024-516817-19-00 9 2025-05-23 Advanced/metastatic solid tumor disease
• A Phase I/II study of GSK5733584 in combination with anti-cancer therapies for advanced solid tumors Recruiting
  2024-517147-31-00 9 2025-05-23 Tumours, Gynecological
• A study Investigating Subcutaneously Administered Pozelimab in Combination with Cemdisiran or Cemdisiran Alone in Adult Participants with Ge … Recruiting
  2023-509547-27-00 5 2025-05-22 Geographic Atrophy Secondary to Age-Related Macular Degeneration
• A Phase 3 Study Comparing BMS-986365 versus Investigator’s Choice of Therapy in Participants with Metastatic Castration-resistant Prostate C … Recruiting
  2024-517422-25-00 5 2025-05-22 Metastatic Castration-resistant Prostate Cancer (mCRPC)
• Long-term study evaluating joint health in people with haemophilia A receiving real-world prophylactic treatment with efanesoctocog alfa Recruiting
  2024-517812-31-00 6 2025-05-21 Haemophilia A
• Randomized, Double Blind, Placebo Controlled "first-in-human" Study to Assess the Safety and Tolerability of Single Ascending Intravenous Do … Recruiting
  2023-504324-26-00 1 2025-05-20 Prevention of infections caused by Gram-negative bacteria
• Phase 1 Study of Revumenib in Combination with Intensive Chemotherapy in Participants with AML Harboring Alterations in KMT2A/MLL, NPM1, or … Recruiting
  2024-514531-18-00 3 2025-05-20 Acute Myeloid Leukemias
• A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) Recruiting
  2024-514937-39-00 5 2025-05-20 Dravet Syndrome
• Phase II clinical trial of chemotherapy + atezolizumab for stage IIIa and IIIb non-small cell lung cancer followed by atezolizumab as adjuva … Recruiting
  2024-515984-68-00 4 2025-05-20 Non-small cell lung cancer (NSCLC)
• Phase II, single arm, multicentre clinical trial to evaluate the activity of encorafenib plus binimetinib followed by Cemiplimab And Fianlim … Recruiting
  2024-513375-40-00 4 2025-05-16 Melanoma
• A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping t … Recruiting
  2024-517584-23-00 9 2025-05-16 Duchenne Muscular Dystrophy
• A clinical study of V940 and pembrolizumab to treat lung cancer (V940-009) Recruiting
  2023-506327-29-00 5 2025-05-14 Non-Small Cell Lung Cancer
• A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia Recruiting
  2024-519822-18-00 10 2025-05-14 Narcolepsy Type 1, Type 2 and Idiopathic Hypersomnia
• A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity Recruiting
  2023-506260-14-00 4 2025-05-13 multiple myeloma
• Study of lunsekimig (SAR443765) compared with placebo in adults with high-risk asthma Recruiting
  2024-513959-33-00 4 2025-05-13 Asthma
• A first time in man study to look at the safety of the experimental drug CCS1477 and what effects it has on cancers that affect the blood, b … Recruiting
  2024-519498-20-00 9 2025-05-13 Acute Myeloid Leukaemia (AML)/higher-risk Myelodysplastic Syndrome (MD
• A Phase 3, multicenter, open label, randomized, non-comparative two-arm study of ivosidenib monotherapy (IVO) and azacitidine monotherapy (A … Recruiting
  2023-510155-37-00 5 2025-05-08 Hypomethylating agent (HMA) naive myelodysplastic syndromes Myelodyspl
• A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adult Patients Wi … Recruiting
  2024-515593-27-00 5 2025-05-08 relapsed or refractory mantle cell lymphoma (R/R MCL)
• Lu177-Dotatate every 16 weeks to reduce adverse events in patients with midgut neuroendocrine tumors Recruiting
  2024-517921-14-00 9 2025-05-07 Neuroendocrine tumors of midgut origin
• Treatment of advanced or metastatic triple negative breast cancer with tumor infiltrating lymphocytes (TILs). Recruiting
  2024-511915-21-01 1 2025-05-05 advanced or metastasic triple-negative breast cancer
• Development of an optimized dosing regimen of ceftazidime-avibactam in critically ill patients treated with continuous renal replacement the … Recruiting
  2023-505536-35-00 6 2025-05-04 Ceftazidime-avibactam therapy in critically ill patients undergoing co

Showing 1,033–1,056 of 3,391 trials